| Bayer (Schweiz) AG - Xarelto junior, Granulat zur Herstellung einer Suspension zum Einnehmen | | 67701 | | 01 | | Xarelto junior | | Granulat zur Herstellung einer Suspension zum Einnehmen | | B01AF01 | | Rivaroxaban | | 02.06.2021 | | |
| | Composition | | rivaroxabanum 1.0 mg, acidum citricum, hypromellosum, mannitolum, cellulosum microcristallinum et carmellosum natricum, E 211 1.8 mg, sucralosum, xanthani gummi, aromatica, maltodextrinum, propylenglycolum, acaciae gummi, ad granulatum corresp. suspensio reconstituta 1 ml corresp. natrium 0.5 mg. | | Packungsbestandteile | | | | | | | | | Inactive agents | Dose | additional_information |
|---|
| | | | | Citric Acid | | | | | | | | Aromatica | | | | Carmellose Sodium | | | | | | | | E 211 | 1.8 mg | conserv. | | Hypromellosum | | | | Maltodextrine | | | | Mannitol | | | | Propylenglycol | | | | | | | | | | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | PR | PR | B | | No | | 002 | | PR | PR | B | | No |
|
|
